Glenmark Pharmaceuticals Ltd 2025 IR

The report highlights Glenmark Pharmaceuticals Limited's transition to Glenmark 3.0, focusing on science-led innovation in oncology, dermatology, and respiratory therapies. In FY 2025, the company achieved consolidated revenues of INR 133,217 million and expanded its global footprint to over 80 countries. Key achievements include the launch of Ryaltris in 11 new markets and a landmark licensing agreement with AbbVie for the oncology asset ISB 2001. On the sustainability front, the company achieved water positivity across its India operations and attained zero waste to landfill at all Indian manufacturing sites ahead of schedule.

Company: Glenmark Pharmaceuticals Ltd

Sector: Health Care

Country: India

Year: 2025

Type: IR

Pages: 412

Back to company

Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd 2025 Integrated Annual Report

Integrated Annual Report

The report highlights Glenmark Pharmaceuticals Limited's transition to Glenmark 3.0, focusing on science-led innovation in oncology, dermatology, and respiratory therapies. In FY 2025, the company achieved consolidated revenues of INR 133,217 million and expanded its global footprint to over 80 countries. Key achievements include the launch of Ryaltris in 11 new markets and a landmark licensing agreement with AbbVie for the oncology asset ISB 2001. On the sustainability front, the company achieved water positivity across its India operations and attained zero waste to landfill at all Indian manufacturing sites ahead of schedule.

Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.

Document Details

Report Year

2025

Reporting Period

Apr 1, 2024 - Mar 31, 2025

Fiscal Year

2025

Type

Integrated Report

Language

English

Pages

 

File Size

 

Standards & Assurance

Reporting Standards

Materiality Assessment

Assurance

Assurance Provider

Assurance Standard

ESG Data?Experimental — AI-extracted data, may contain inaccuracies

Emissions

Scope 1:

Scope 2:

Scope 3:

Energy Consumption

Water Consumption

Total Waste

Women on Board

Women in Management

Workplace Fatalities

Net Zero Target

Employees